Medicenna Therapeutics (TSE:MDNA) Insider Purchases C$11,200.00 in Stock

Medicenna Therapeutics Corp. (TSE:MDNA) insider David Hyman purchased 10,000 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was bought at an average price of C$1.12 per share, for a total transaction of C$11,200.00. Following the completion of the transaction, the insider directly owned 50,000 shares in the company, valued at approximately C$56,000. The trade was a 25.00% increase in their ownership of the stock.

Medicenna Therapeutics Stock Performance

Shares of TSE:MDNA traded down C$0.01 on Monday, hitting C$1.09. 158,893 shares of the company were exchanged, compared to its average volume of 61,393. The company’s 50 day moving average price is C$1.33 and its two-hundred day moving average price is C$1.09. The firm has a market capitalization of C$90.92 million, a price-to-earnings ratio of -6.41 and a beta of 3.31. The company has a debt-to-equity ratio of 0.88, a quick ratio of 4.65 and a current ratio of 11.40. Medicenna Therapeutics Corp. has a one year low of C$0.78 and a one year high of C$1.98.

Medicenna Therapeutics (TSE:MDNA) last released its earnings results on Thursday, November 13th. The company reported C($0.06) earnings per share for the quarter. Medicenna Therapeutics had a negative return on equity of 159.88% and a negative net margin of 533,640.00%. Research analysts expect that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.